The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital

References

• LaurettiLRM, MazzariolA. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother. 1999;43:1584–1590. doi:10.1128/AAC.43.7.158410390207
   PubMed Web of Science ®Google Scholar
• OsanoEAY, WacharotayankunR. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother. 1994;38.8141577
   PubMed Web of Science ®Google Scholar
• Munoz-PriceLSPL, BonomoRA. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–796. doi:10.1016/S1473-3099(13)70190-723969216
   PubMed Web of Science ®Google Scholar
• PoirelLHC, TolünV, NordmannP. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:15–22. doi:10.1128/AAC.48.1.15-22.200414693513
   PubMed Web of Science ®Google Scholar
• YongDTM, GiskeCG. Characterization of a new metallo-betalactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046–5054. doi:10.1128/AAC.00774-0919770275
   PubMed Web of Science ®Google Scholar
• RanjanASS, MondalA. Molecular epidemiology and genome dynamics of New Delhi metallo-β-lactamase-producing extraintestinal pathogenic Escherichia coli strains from India. Antimicrob Agents Chemother. 2016;60:6795–6805. doi:10.1128/AAC.01345-1627600040
   PubMed Web of Science ®Google Scholar
• BushK, JacobyGA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969–976. doi:10.1128/AAC.01009-0919995920
   PubMed Web of Science ®Google Scholar
• LoganLK, WeinsteinRA. The epidemiology of Carbapenem-Resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–s36. doi:10.1093/infdis/jiw28228375512
   PubMed Web of Science ®Google Scholar
• van DuinD, DoiY. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460–469. doi:10.1080/21505594.2016.122234327593176
   PubMed Web of Science ®Google Scholar
• NetikulT, KiratisinP. Genetic characterization of Carbapenem-Resistant Enterobacteriaceae and the spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a university hospital in Thailand. PLoS One. 2015;10(9):e0139116. doi:10.1371/journal.pone.013911626407326
   PubMed Web of Science ®Google Scholar
• RimrangB, ChanawongA, LulitanondA, et al. Emergence of NDM-1- and IMP-14a-producing Enterobacteriaceae in Thailand. J Antimicrob Chemother. 2012;67(11):2626–2630. doi:10.1093/jac/dks26722796889
   PubMed Web of Science ®Google Scholar
• Antibiogram 2018–2019. National Surveillance System for. Antimicrobial Resistance. Thailand; 2019. Available from: http://narst.dmsc.moph.go.th/. Accessed 622, 2020.
   Google Scholar
• LaolerdW, AkedaY, PreeyanonL, RatthawongjirakulP, SantanirandP. Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae from Bangkok, Thailand, and their detection by the Carba NP and modified Carbapenem Inactivation Method Tests. Microb Drug Resist. 2018;24(7):1006–1011. doi:10.1089/mdr.2018.008029782216
   PubMed Web of Science ®Google Scholar
• FalconeM, PatersonD. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71(10):2713–2722. doi:10.1093/jac/dkw23927432599
   PubMed Web of Science ®Google Scholar
• SaderHS, CastanheiraM, ShortridgeD, MendesRE, FlammRK. Antimicrobial activity of Ceftazidime-Avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016. Antimicrob Agents Chemother. 2017;61(11). doi:10.1128/AAC.01045-17
   Web of Science ®Google Scholar
• WongD, van DuinD. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs. 2017;77(6):615–628. doi:10.1007/s40265-017-0725-128303449
   PubMed Web of Science ®Google Scholar
• van DuinD, BonomoRA. Ceftazidime-avibactam and Ceftolozane/Tazobactam: second-generation β-Lactam/β-Lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234–241.27098166
   PubMed Web of Science ®Google Scholar
• TammaPD, AitkenSL, BonomoRA, MathersAJ, van DuinD, ClancyCJ. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2020;27:ciaa1478.
   Google Scholar
• TemkinE, Torre-CisnerosJ, BeovicB, et al. Ceftazidime-Avibactam as salvage therapy for infections caused by Carbapenem-Resistant organisms. Antimicrob Agents Chemother. 2017;61(2):e01964–01916. doi:10.1128/AAC.01964-1627895014
   PubMed Web of Science ®Google Scholar
• The National Antimicrobial Resistant Surveillance Thailand. Antibiogram; Published 2019. Available from: http://narst.dmsc.moph.go.th/. Accessed 410, 2020.
   Google Scholar
• SantimaleeworagunW, ThunyaharnS, JuntanawiwatP, et al. The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia. J Appl Pharm Sci. 2020;10(2):56–59.
   Google Scholar
• Performance standards for antimicrobial susceptibility testing; 30th ed. CLSI supplement M100. Clinical and Laboratory Standard Institute; 2020. Available from: https://clsi.org. Accessed 520, 2020.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 11; Published 2021. Available from: http://www.eucast.org/clinical_breakpoints/. Accessed 318, 2021.
   Google Scholar
• Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). Update - CRE Toolkit 2015. Centers for Disease Control and Prevention; 2015. Available from: www.cdc.gov. Accessed 522, 2020.
   Google Scholar
• ShieldsRK, ClancyCJ, PasculleAW, et al. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam susceptibility testing methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2018;56(2). doi:10.1128/JCM.01093-17.
   Web of Science ®Google Scholar
• PatelJB, SharpS, Novak-WeekleyS. Verification of antimicrobial susceptibility testing methods: a practical approach. Clin Microbiol Newsl. 2013;35(13):103–109. doi:10.1016/j.clinmicnews.2013.06.001
   Google Scholar
• PoirelL, WalshTR, CuvillierV, NordmannP. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–123. doi:10.1016/j.diagmicrobio.2010.12.00221398074
   PubMed Web of Science ®Google Scholar
• LiuYY, WangY, WalshTR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168. doi:10.1016/S1473-3099(15)00424-726603172
   PubMed Web of Science ®Google Scholar
• SteinGE, SmithCL, ScharmenA, et al. Pharmacokinetic and pharmacodynamic analysis of Ceftazidime-avibactam in critically ill patients. Surg Infect (Larchmt). 2019;20(1):55–61. doi:10.1089/sur.2018.14130351195
   PubMed Web of Science ®Google Scholar
• NicholsWW, NewellP, CritchleyIA, RiccobeneT, DasS. Avibactam pharmacokinetic/pharmacodynamic targets. Antimicrob Agents Chemother. 2018;62(6). doi:10.1128/AAC.02446-17
   Web of Science ®Google Scholar
• MorrillHJ, PogueJM, KayeKS, LaPlanteKL. Treatment options for Carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis. 2015;2(2):ofv050–ofv050. doi:10.1093/ofid/ofv05026125030
   PubMed Web of Science ®Google Scholar
• Rodríguez-BañoJ, Gutiérrez-GutiérrezB, MachucaI, PascualA. Treatment of infections caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079–00017. doi:10.1128/CMR.00079-1729444952
   PubMed Web of Science ®Google Scholar
• SonnevendÁ, GhazawiA, DarwishD, et al. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Int J Infect Dis. 2020;99:253–259. doi:10.1016/j.ijid.2020.07.05032738488
   PubMed Web of Science ®Google Scholar
• ZouC, WeiJ, ShanB, ChenX, WangD, NiuS. In vitro activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-resistant Enterobacteriaceae isolates collected from three secondary hospitals in Southwest China Between 2018 and 2019. Infect Drug Resist. 2020;13:3563–3568. doi:10.2147/IDR.S27398933116675
   PubMed Web of Science ®Google Scholar
• KimT, LeeSC, BaeM, et al. In vitro activities and inoculum effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-resistant Enterobacteralesisolates from South Korea. Antibiotics (Basel. 2020;9(12). doi:10.3390/antibiotics9120912.
   Web of Science ®Google Scholar
• SaderHS, RhombergPR, ChandrasekaranS, et al. Correlation between broth microdilution and disk diffusion results when testing Ceftazidime-Avibactam against a challenge collection of Enterobacterales isolates: results from a multilaboratory study. J Clin Microbiol. 2020;58(4). doi:10.1128/JCM.01757-19.
   Web of Science ®Google Scholar
• RojasLJ, SalimM, CoberE, et al. Colistin resistance in Carbapenem-Resistant Klebsiella pneumoniae: laboratory detection and impact on Mortality. Clin Infect Dis. 2017;64(6):711–718. doi:10.1093/cid/ciw80527940944
   PubMed Web of Science ®Google Scholar
• AmladiAU, AbiramiB, DeviSM, et al. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections. Indian J Med Res. 2019;149(2):185–191. doi:10.4103/ijmr.IJMR_2086_1731219082
   PubMed Web of Science ®Google Scholar
• BialvaeiAZ, Samadi KafilH. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015;31(4):707–721. doi:10.1185/03007995.2015.101898925697677
   PubMed Web of Science ®Google Scholar
• SoukupP, FaustAC, EdpugantiV, PutnamWC, McKinnellJA. Steady-State Ceftazidime-Avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration. Pharmacotherapy. 2019;39(12):1216–1222. doi:10.1002/phar.233831596506
   PubMed Web of Science ®Google Scholar